A2A at BiopharmaA2A PharmaMay 16, 20191 min readUpdated: Feb 7, 2020A2A participated at the AI Applications Summit Biopharma discussing the urgency to advance AI applications in industry to bring benefits to patients fasterLEARN MORE
A2A TACC3 Program Clinical Progress in Womens CancersMay 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...
A2A co-founded biomea Fusion raises $56MBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...
Comments